尼妥珠单抗在鼻咽癌治疗中的应用进展  

Progress of Nimotuzumab Application in Nasopharyngeal Carcinoma

作　　者：梁天赐 赵悦 宋陈晨 张超贻 陈晨[1,2] 李俏苒 戎彪学 LIANG Tianci;ZHAO Yue;SONG Chenchen;ZHANG Chaoyi;CHEN Chen;LIQiaoran;RONG Biaoxue(Department of Oncology,The First Affiliated Hospital of Xi'an Medical University,Xi'an 710077,China;Graduate School of Xi'an Medical University,Xi'an 710077,China)

机构地区：[1]西安医学院第一附属医院肿瘤内科,西安710077 [2]西安医学院研究生院,西安710077

出　　处：《肿瘤防治研究》2024年第11期956-961,共6页Cancer Research on Prevention and Treatment

基　　金：陕西省科技计划(面上项目)(2021JM-491);西安市科技计划项目(20YXYJ0001-8)。

摘　　要：我国鼻咽癌的发病率高于世界平均发病率,尤其在我国南方地区,该病的死亡率长期居高不下。尼妥珠单抗作为作用于表皮生长因子受体(EGFR)的靶向治疗药物,在鼻咽癌治疗领域不断进展。近年来,大量研究显示,尼妥珠单抗与传统放化疗方案联合,能够提高治疗效果,降低不良反应,改善患者生活质量,本文从此角度出发,总结当前研究成果,以期为鼻咽癌的治疗提供更好的诊疗思路。Compared with the global average,the incidence rate of nasopharyngeal carcinoma(NPC)in China is higher,particularly in the southern regions where the mortality rate has remained persistently high.Nimotuzumab,a targeted therapy that acts on the epidermal growth factor receptor,has prompted continuous progress in NPC treatment.The combination of nimotuzumab with traditional radiotherapy and chemo-therapy can enhance treatment efficacy,reduce adverse reactions,and improve patients’quality of life.This article summarizes current research findings from this perspective to provide diagnostic and therapeutic strategies for NPC treatment.

关 键 词：鼻咽癌 尼妥珠单抗 表皮生长因子受体 靶向治疗 抗肿瘤治疗 

分 类 号：R739.6[医药卫生—肿瘤]